Abstracts Archive - Page 1980 of 2607 - ACR Meeting Abstracts

Abstract Number: 1638 • 2015 ACR/ARHP Annual Meeting
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…
Abstract Number: 1639 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Roy Fleischmann¹, Yusuf Yazici², Jürgen Wollenhaupt³, Lisy Wang⁴, Anna Maniccia⁵, Kenneth Kwok⁴, Liza Takiya⁵ and Ronald van Vollenhoven⁶, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²New York University Hospital for Joint Diseases, New York, NY, ³Teaching Hospital of the University of Hamburg, Schoen-Klinik Hamburg-Eilbek, Hamburg, Germany, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…
Abstract Number: 1640 • 2015 ACR/ARHP Annual Meeting
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Philip J. Mease², Sergio Schwartzman³, Lie-Ju Hwang⁴, Aditya Patel⁵, Koshika Soma⁴, Carol A. Connell⁶, Liza Takiya⁴ and Eustratios Bananis⁷, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Hospital for Special Surgery, New York, NY, ⁴Pfizer Inc, New York, NY, ⁵Inventiv Health Inc, South Plainfield, NJ, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). ORAL Scan was a 2-year, randomized, Phase 3, clinical trial…
Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson³ and Jeremy Sokolove⁴, ¹Rheumatology, University College London, London, United Kingdom, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
Abstract Number: 1642 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate Inadequate Responders with Rheumatoid Arthritis
Roy Fleischmann¹, Janet E. Pope², Vanita Tongbram³, Derek Tang⁴, James Chung⁵, David Collier⁵, Shilpa Urs³, Kerigo Ndirangu³, George A. Wells⁶ and Ronald F. van Vollenhoven⁷, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²University of Western Ontario, London, ON, Canada, ³ICON Plc., Morristown, NJ, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁷Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Previously published rheumatoid arthritis (RA) trials in which TNFi-MTX and triple therapy (MTX + hydroxychloroquine + sulfasalazine) were included as treatment arms in MTX…
Abstract Number: 1643 • 2015 ACR/ARHP Annual Meeting
Modified-Release Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-Release Tofacitinib and Impact of Food
Manisha Lamba¹, Rong Wang¹, Tracey Fletcher², Christine Alvey¹, Joseph Kushner¹ and Thomas Stock², ¹Pfizer Inc, Groton, CT, ²Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A modified-release (MR) formulation has been designed to enable once daily (QD)…
Abstract Number: 1644 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Yusuf Yazici¹, KK Gandhi², E Alemao² and Daniel E. Furst³, ¹NYU Hospital for Joint Diseases, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) comprises the three patient-reported ACR RA Core Data Set measures: function (HAQ-DI), pain and patient global…
Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Irina Lazariciu⁶, Chudy Nduaka⁷, Carol A. Connell⁴, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…
Abstract Number: 1646 • 2015 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting? the ACT-Solo Study: An Analysis of Efficacy and Safety at 12 Months
Jacques Tebib¹, Isabelle Idier², Mathieu Coudert³, David Pau⁴, Jean-Francis Maillefert⁵ and Rene-Marc Flipo⁶, ¹Rheumatology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France, ²Chugai Pharma, La Defense, France, ³Statistics, Experis IT, Nanterre, France, ⁴Statistics, Roche, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospital, Dijon, France, ⁶Rheumatology, University Hospital, Lille, France
Background/Purpose: Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Kara Bickham¹, Désirée van der Heijde², Narinder Rawal³, Joachim Sieper⁴, Boyd Scott⁵, Nancy Frontera¹, Sandhya Shah¹, Paul Stryszak¹, Dimitris Papanicolaou¹, Zoran Popmihajlov¹ and Paul Peloso¹, ¹Merck & Co., Inc., Kenilworth, NJ, ²University Hospital, Maastricht, Netherlands, ³Orebro University Hospital, Orebro, Sweden, ⁴Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…
Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting
The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis
Yoshifumi Tada¹, Syuichi Koarada², Nobuyuki Ono², Akihito Maruyama², Satoko Tashiro², Yukiko Tokuda², Yukihide Ono², Yoshinobu Nakao² and Akihide Ohta³, ¹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ²Rheumatology, Saga University, Saga, Japan, ³Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan
Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
Abstract Number: 1649 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
Mark C. Genovese¹, Roy Fleischmann², Yoshiya Tanaka³, Daniel E. Furst⁴, Hisashi Yamanaka⁵, Rajesh Joshi⁶, Wei Zhu⁷, Jing Shao⁸, Hideki Mashimo⁸ and Tsutomu Takeuchi⁹, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Quintiles Inc., Mumbai, India, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Tokyo, Japan, ⁹Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Olokizumab (OKZ) is a humanized anti-interleukin-6 monoclonal antibody in development for moderate-to-severe rheumatoid arthritis (RA) treatment. OKZ efficacy and safety were assessed in the…
Abstract Number: 1650 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy in Early Rheumatoid Arthritis: Data from Two Phase 3 Randomized Controlled Trials
Gerd Burmester¹, Attila Pethö-Schramm², Caroline Keane³ and Graeme Jones⁴, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁴Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Disease remission is the current treatment goal for patients (pts) with early RA (eRA). Initiation of an anti-TNF agent ± methotrexate (MTX) is recommended…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 1652 • 2015 ACR/ARHP Annual Meeting
A HPLC-SRM-MS Based Method for the Detection of Adherence to Low-Dose Oral Methotrexate
James Bluett¹, Thierry Wendling², Kayode Ogungbenro², Isabel Riba-Garcia³, Richard Unwin³, Suzanne M. Verstappen⁴ and Anne Barton^5,6, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, The University of Manchester, Manchester, United Kingdom, ³Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Whilst methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA), response is not universal. Rates of adherence reported in the literature range from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].